First Bank & Trust reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.2% during the first quarter, Holdings Channel reports. The fund owned 1,725 shares of the biopharmaceutical company’s stock after selling 239 shares during the period. First Bank & Trust’s holdings in Gilead Sciences were worth $117,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Hall Laurie J Trustee increased its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares in the last quarter. Cable Hill Partners LLC increased its stake in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares in the last quarter. Dubuque Bank & Trust Co. increased its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. bought a new stake in Gilead Sciences during the fourth quarter valued at $143,000. Finally, Perennial Advisors LLC bought a new stake in Gilead Sciences during the fourth quarter valued at $150,000. 73.99% of the stock is owned by institutional investors and hedge funds.
Gilead Sciences, Inc. (NASDAQ GILD) opened at 65.59 on Wednesday. The firm has a 50 day moving average of $65.46 and a 200-day moving average of $69.00. The firm has a market cap of $85.71 billion, a P/E ratio of 6.93 and a beta of 1.20. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $88.85. Gilead Sciences also was the target of some unusual options trading activity on Monday. Stock investors acquired 22,560 call options on the stock. This is an increase of approximately 103% compared to the average volume of 11,118 call options.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.18 by $0.02. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.66 billion. Gilead Sciences had a net margin of 43.42% and a return on equity of 76.64%. On average, equities research analysts forecast that Gilead Sciences, Inc. will post $8.35 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 29th. Stockholders of record on Friday, June 16th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 3.17%. The ex-dividend date of this dividend is Wednesday, June 14th. Gilead Sciences’s payout ratio is 21.99%.
WARNING: “Gilead Sciences, Inc. (GILD) Stake Cut by First Bank & Trust” was first published by sleekmoney and is the property of of sleekmoney. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://sleekmoney.com/gilead-sciences-inc-gild-stake-cut-by-first-bank-trust/1926793.html.
Several analysts have recently weighed in on the stock. William Blair reaffirmed an “outperform” rating on shares of Gilead Sciences in a research note on Friday, June 16th. ValuEngine downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Credit Suisse Group reaffirmed an “outperform” rating and set a $79.00 price target on shares of Gilead Sciences in a research note on Monday, May 15th. Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.34 price target for the company. in a research note on Thursday, May 11th. Finally, Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, May 5th. Twelve investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $80.61.
In related news, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction dated Thursday, March 30th. The shares were sold at an average price of $67.48, for a total value of $337,400.00. Following the completion of the sale, the executive vice president now owns 117,988 shares in the company, valued at $7,961,830.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John Francis Cogan sold 9,943 shares of the firm’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $67.25, for a total transaction of $668,666.75. Following the completion of the sale, the director now owns 47,562 shares of the company’s stock, valued at approximately $3,198,544.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 88,276 shares of company stock worth $5,932,578. Insiders own 1.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/gilead-sciences-inc-gild-stake-cut-by-first-bank-trust/1926793.html
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.